{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T14:11:21Z","timestamp":1784729481764,"version":"3.55.0"},"reference-count":73,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2018,3,23]],"date-time":"2018-03-23T00:00:00Z","timestamp":1521763200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:p>Model\u2010informed drug development (MIDD) was central to the development of the oral proteasome inhibitor ixazomib, facilitating internal decisions (switch from body surface area (BSA)\u2010based to fixed dosing, inclusive phase III trials, portfolio prioritization of ixazomib\u2010based combinations, phase III dose for maintenance treatment), regulatory review (model\u2010informed QT analysis, benefit\u2013risk of 4\u2009mg dose), and product labeling (absolute bioavailability and intrinsic\/extrinsic factors). This review discusses the impact of MIDD in enabling patient\u2010centric therapeutic optimization during the development of ixazomib.<\/jats:p>","DOI":"10.1002\/cpt.1047","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T08:02:59Z","timestamp":1518681779000},"page":"376-387","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Model\u2010Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor"],"prefix":"10.1111","volume":"105","author":[{"given":"Neeraj","family":"Gupta","sequence":"first","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Hanley","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Diderichsen","sequence":"additional","affiliation":[{"name":"Certara Strategic Consulting Breda The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyuan","family":"Yang","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ke","sequence":"additional","affiliation":[{"name":"Certara USA, Inc. Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyang","family":"Teng","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Labotka","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Berg","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chirag","family":"Patel","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guohui","family":"Liu","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi","family":"van de Velde","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthik","family":"Venkatakrishnan","sequence":"additional","affiliation":[{"name":"Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,3,23]]},"reference":[{"key":"e_1_2_14_1_1","unstructured":"Millennium Pharmaceuticals Inc.NINLARO\u00ae (ixazomib) capsules for oral use. United States Prescribing Information.2016."},{"key":"e_1_2_14_2_1","unstructured":"Takeda Pharma A\/S.NINLARO: European Product Assessment Report (EPAR) \u2014 Product Information. Annex I \u2014 Summary of Product Characteristics.2017."},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516282"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-548941"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-548826"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0198-1"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12527"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12049"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.7"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.40"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12674"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.52"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12056"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13119"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12171"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0526-4"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12542"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.988"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2815-7"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-016-0346-7"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-017-0524-3"},{"key":"e_1_2_14_22_1","first-page":"643","article-title":"Model\u2010based meta\u2010analysis for multiple myeloma: a quantitative drug\u2010independent framework for efficient decisions in oncology drug development","volume":"12","author":"Teng Z.","year":"2017","journal-title":"Clin. Transl. Sci"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-8-913"},{"key":"e_1_2_14_24_1","unstructured":"Millennium Pharmaceuticals Inc.VELCADE\u00ae (bortezomib) for injection for subcutaneous or intravenous use.2017."},{"key":"e_1_2_14_25_1","unstructured":"Onyx Pharmaceuticals Inc.KYPROLIS\u00ae (carfilzomib) for injection for intravenous use.2017."},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2863"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14125"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12991"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.259"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1880"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1078"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2516-z"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1010639201787"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.12"},{"key":"e_1_2_14_35_1","unstructured":"US FDA Center for Drug Evaluation and Research.Clinical pharmacology and biopharmaceutics reviews application number 203585Orig1s000: Omacetaxine mepesuccinate.2012."},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2016.1151351"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006286436"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000340050"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12677"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cardfail.2014.11.008"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007307881"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.60"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/anec.12128"},{"key":"e_1_2_14_44_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.7.3.305"},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.14"},{"key":"e_1_2_14_46_1","unstructured":"United States Food and Drug Administration.E14 Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non\u2010Antiarrhythmic Drugs \u2014 Questions and Answers (R3) Guidance for Industry.2017."},{"key":"e_1_2_14_47_1","unstructured":"Australian Government \u2014 Department of Health Therapeutic Goods Administration.Guidance 15: Biopharmaceutic studies.2015."},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2016.04.004"},{"key":"e_1_2_14_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0188-4"},{"key":"e_1_2_14_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0330-y"},{"key":"e_1_2_14_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-015-2931-4"},{"key":"e_1_2_14_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.153"},{"key":"e_1_2_14_53_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.9"},{"key":"e_1_2_14_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-717769"},{"key":"e_1_2_14_55_1","first-page":"317","article-title":"Twice\u2010weekly ixazomib plus lenalidomide\u2010dexamethasone in patients with newly diagnosed multiple myeloma: long\u2010term follow\u2010up data for patients who did not undergo stem cell transplantation","volume":"102","author":"Richardson P.","year":"2017","journal-title":"Haematologica"},{"key":"e_1_2_14_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1295"},{"key":"e_1_2_14_57_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.10624.3"},{"key":"e_1_2_14_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13327"},{"key":"e_1_2_14_59_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181b2c8cf"},{"key":"e_1_2_14_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.015"},{"key":"e_1_2_14_61_1","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.15.78"},{"key":"e_1_2_14_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.013"},{"key":"e_1_2_14_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.014"},{"key":"e_1_2_14_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71125-8"},{"key":"e_1_2_14_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.04.031"},{"key":"e_1_2_14_66_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS8068"},{"key":"e_1_2_14_67_1","article-title":"Clinical development success rates 2006\u20102015","author":"Thomas D.W.","year":"2016","journal-title":"BIO Biomedtracker Amplion"},{"key":"e_1_2_14_68_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0124"},{"key":"e_1_2_14_69_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2012.122"},{"key":"e_1_2_14_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2011.242"},{"key":"e_1_2_14_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.14"},{"key":"e_1_2_14_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2015.12.008"},{"key":"e_1_2_14_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not236"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1047","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1047","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1047","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T13:36:07Z","timestamp":1699364167000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,23]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["10.1002\/cpt.1047"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1047","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,23]]},"assertion":[{"value":"2017-11-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}